ALAM
NBIX icon

Asahi Life Asset Management’s Neurocrine Biosciences NBIX Stock Holding History

Asahi Life Asset Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-3,285
Closed -$378K – 206
2024
Q3 		$378K Buy
+3,285
New +$450K 0.23% 117
2023
Q4 		– Sell
-2,565
Closed -$289K – 214
2023
Q3 		$289K Sell
2,565
-575
-18% -$60.5K 0.1% 130
2023
Q2 		$296K Buy
3,140
+500
+19% +$48.9K 0.1% 150
2023
Q1 		$267K Buy
+2,640
New +$275K 0.08% 164

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Asahi Life Asset Management's NBIX Position: Q4 2024 in Review

Asahi Life Asset Management sold out of Neurocrine Biosciences (NBIX) in Q4 2024, closing a stake of 3,285 shares — an estimated $378K sold.

Asahi Life Asset Management first reported a position in NBIX in Q1 2023 and held it in 4 quarters. The position peaked at $378K in Q3 2024. 600 funds tracked by Wall St. Rank hold NBIX as of Q4 2024.

  • Asahi Life Asset Management reported no remaining Neurocrine Biosciences position as of Q4 2024 after selling out during the quarter.
  • Asahi Life Asset Management sold 3,285 Neurocrine Biosciences shares in Q4 2024, an estimated $378K.
  • Asahi Life Asset Management first reported a position in Neurocrine Biosciences in Q1 2023 and held it in 4 quarters.
  • Asahi Life Asset Management's Neurocrine Biosciences position peaked at $378K in Q3 2024.
  • 600 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2024.

Based on Asahi Life Asset Management's 13F filing for Q4 2024, filed 5 Feb 2025.